Prevention of Microvascular Thrombosis by Topical Application of Recombinant Tissue Factor Pathway Inhibitor
- 1 March 1996
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Plastic and Reconstructive Surgery
- Vol. 97 (3), 587-594
- https://doi.org/10.1097/00006534-199603000-00015
Abstract
Tissue factor pathway inhibitor is a naturally occurring protein inhibitor of factor X and the tissue factor-factor VII complex of the extrinsic pathway of coagulation. The potential of tissue factor pathway inhibitor as a topical antithrombotic agent was evaluated in a rabbit model of thrombosis that combined intimal injury, anastomosis, and a twisted pedicle. In 207 rabbit ears, a near-complete amputation was performed, preserving the central ear artery and vein. The central ear artery was transected, the intima was removed mechanically over a 1-cm length, the artery was anastomosed, and the ear was twisted 360 degrees, wrapping the intact vein around the artery. Before recirculation, the lumen was irrigated on a blinded, randomized basis with either hirudin (100 or 500 units/ml), heparin (50 or 100 units/ml), tissue factor pathway inhibitor (10, 40, 125, or 250 microgram/ml), heparin and tissue factor pathway inhibitor together, or vehicle (control). Upon arterial reflow, the ears were observed for 7 days. Patency rates after 7 days were as follows: hirudin, 30 and 55 percent; heparin, 43 and 50 percent; tissue factor pathway inhibitor, 75 and 90 percent; heparin and tissue factor pathway inhibitor, 75 percent; and vehicle, 6 percent. The higher concentrations of tissue factor pathway inhibitor led to significantly higher patency rates than heparin, hirudin, or control solutions. Electron microscopic evaluation of specimens irrigated with gold- labeled tissue factor pathway inhibitor revealed the inhibitor bound to the injured intimal surface for at least 3 days postoperatively. Coagulation studies showed no change in the clotting profile upon intravascular infusion with tissue factor pathway inhibitor even at the highest dose used topically. We conclude that tissue factor pathway inhibitor is a more effective topical antithrombotic agent than either heparin or hirudin.Keywords
This publication has 34 references indexed in Scilit:
- Experimental Reproduction of Free Flap Errors: A New Model of ThrombosisAnnals of Plastic Surgery, 1994
- Prevention of Thrombosis by Topical Application of Tissue Factor Pathway Inhibitor in a Rabbit Model of Vascular TraumaAnnals of Plastic Surgery, 1993
- Future alternatives to heparin: Low-molecular-weight heparin and hirudinJournal of Vascular Surgery, 1992
- Antithrombotic benefit of subendothelium-bound urokinase: An experimental studyThe Journal of Hand Surgery, 1992
- Washout of Vessels with Heparin Does Not Improve Patency Following Severe Microarterial Trauma: An Experimental StudyAnnals of Plastic Surgery, 1990
- A comparison of irrigation solutions for microanastomosesThe Journal of Hand Surgery, 1988
- Effectiveness of AnticoagulantsSeminars in Thrombosis and Hemostasis, 1986
- Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.JCI Insight, 1985
- Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen γ chainBiochemical and Biophysical Research Communications, 1982
- Thrombosis: the relationship of hemostatic mechanisms to drug therapyJournal of Neurosurgery, 1981